Increased mRNA expression of interferon-induced Mx1 and immunomodulation following oral administration of IFN-α2b-transformed B. longum to mice

Archives of Microbiology

Volumn 192, Issue 8, 2010, Pages 633-638

  Yu, Zhijian ^a   Zeng, Zhongming ^a   Huang, Zhen ^a   Lian, Jie ^a   Yang, Jin ^a   Deng, Qiwen ^a   Zeng, Weiseng ^b  

^a Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bifidobacterium breve; Immunomodulation; Interferon 2b; Mx1 gene; Peyer's patch cell

Indexed keywords

ALPHA2B INTERFERON; GENE PRODUCT; INTERFERON; MESSENGER RNA; PEGINTERFERON ALPHA2A; PROBIOTIC AGENT; PROTEIN MX1; UNCLASSIFIED DRUG; ALPHA INTERFERON; CYTOKINE; GUANINE NUCLEOTIDE BINDING PROTEIN; MX1 PROTEIN, MOUSE; MYXOVIRUS RESISTANCE PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM TRANSFORMATION; BIFIDOBACTERIUM LONGUM; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE RELEASE; FECES LEVEL; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE LEVEL; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; BLOOD; CYTOLOGY; GENETICS; INTESTINE; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PEYER PATCH; SECRETION (PROCESS); SPLEEN;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; CYTOKINES; GTP-BINDING PROTEINS; IMMUNOMODULATION; INTERFERON ALFA-2B; INTESTINES; LIVER; MALE; MICE; MICE, INBRED BALB C; PEYER'S PATCHES; PROBIOTICS; RNA, MESSENGER; SPLEEN; TRANSCRIPTION, GENETIC; INTERFERON-ALPHA; MYXOVIRUS RESISTANCE PROTEINS; RECOMBINANT PROTEINS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; MUS;

EID: 77956229821     PISSN: 03028933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00203-010-0589-1     Document Type: Article

References (24)

1. D Alignani B Maletto M Liscovsky A Rópolo G Morón MC Pistoresi-Palencia 2005 Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice J Leukocyte Biol 77 898 905 10.1189/jlb.0604330 1:CAS:528:DC%2BD2MXltValtbg%3D 15758079
2. M Bollati-Fogolín W Müller 2005 Virus free, cell-based assay for the quantification of murine type I interferons J Immunol Methods 306 169 175 10.1016/j.jim.2005.08.005 16209875
3. SA Brod 2002 Ingested type I interferon: a potential treatment for autoimmunity J Interferon Cytokine Res 22 1153 1166 10.1089/10799900260475669 1:CAS:528:DC%2BD3sXhtlChsrg%3D 12581487
4. SA Brod DK Burns 1994 Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of Type I Interferons Neurology 44 1144 1148 1:CAS:528:DyaK2cXlsFGmsbY%3D 8208413
5. JM Cummins GS Krakowka CG Thompson 2005 Systemic effects of interferons after oral administration in animals and humans Am J Vet Res 66 164 176 10.2460/ajvr.2005.66.164 15691053
6. David RL (2007-2008) CRC handbook of chemistry and physics. In: 88th edn, CRC Press, Boca Raton, pp 110
7. M Dec A Puchalski 2008 Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases Pol J Vet Sci 11 175 186 1:CAS:528:DC%2BD1cXht1ems77L 18683548
8. Q Deng W Zeng Z Yu 2009 Signal peptide of Arabinosidase enhances secretion of interferon-alpha2b protein by Bifidobacteria longum Arch Microbiol 191 681 686 10.1007/s00203-009-0496-5 1:CAS:528:DC%2BD1MXhtVWhsLvN 19652954
9. P Eid JF Meritet C Maury A Lasfar D Weill MG Tovey 1999 Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics J Interferon Cytokine Res 19 157 169 10.1089/107999099314306 1:CAS:528:DyaK1MXhs1Wqt7Y%3D 10090401
10. KA Forde KR Reddy 2009 Hepatitis C virus infection and immunomodulatory therapies Clin Liver Dis 13 391 401 10.1016/j.cld.2009.05.007 19628156
11. B Hu L Kou C Li LP Zhu YR Fan ZW Wu JJ Wang GX Xu 2009 Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth Cancer Gene Ther 16 655 663 10.1038/cgt.2009.7 1:CAS:528:DC%2BD1MXitFKksb4%3D 19229287
12. JB Jørgensen A Johansen MN Hegseth J Zou B Robertsen B Collet CJ Secombes 2007 A recombinant CHSE-214 cell line expressing an Mx1 promoter-reporter system responds to both interferon type I and type II from salmonids and represents a versatile tool to study the IFN-system in teleost fish Fish Shellfish Immunol 23 1294 1303 10.1016/j.fsi.2007.07.008 17804253
13. H Kiliç HE Zeytin C Korkmaz C Mat A Gül F Coşan A Dinç I Simşek N Süt H Yazici 2009 Low-dose natural human interferon-alpha lozenges in the treatment of Behçet's syndrome Rheumatology (Oxford) 48 1388 1391 10.1093/rheumatology/kep237
14. A Meager 2002 Biological assays for interferons J Immunol Methods 261 21 36 10.1016/S0022-1759(01)00570-1 1:CAS:528:DC%2BD38Xhtlektbg%3D 11861063
15. JM Meijer J Pijpe H Bootsma A Vissink CG Kallenberg 2007 The future of biologic agents in the treatment of Sjögren's syndrome Clin Rev Allergy Immunol 32 292 297 10.1007/s12016-007-8005-6 1:CAS:528:DC%2BD1cXitFeq 17992596
16. AR Pachner A Bertolotto F Deisenhammer 2003 Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB) Neurology 61 9 Suppl 5 S24 S26 1:CAS:528: DC%2BD3sXot12htb8%3D 14610107
17. H Petry L Cashion P Szymanski O Ast A Orme C Gross M Bauzon A Brooks C Schaefer H Gibson H Qian GM Rubanyi RN Harkins 2006 Mx1 and IP-10: biomarkers to measure IFN-beta activity in mice following gene-based delivery J Interferon Cytokine Res 26 699 705 10.1089/jir.2006.26.699 1:CAS:528:DC%2BD28XhtVGktbvP 17032164
18. C Polman F Barkhof L Kappos C Pozzilli R Sandbrink, et al. 2003 Oral interferon beta-1a in relapsing -remitting multiple sclerosis: a double-blind randomized study Mult Scler 9 342 348 10.1191/1352458503ms923oa 1:CAS:528:DC%2BD3sXntV2ltbs%3D 12926838
19. ML Reyes Escogido A De León Rodríguez AP Barba de la Rosa 2007 A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum Biotechnol Lett 29 1249 1253 10.1007/s10529-007-9376-8 1:CAS:528:DC%2BD2sXnt1KitLY%3D 17487549
20. AN Shkoporov BA Efimov EV Khokhlova LI Kafarskaia VV Smeianov 2008 Production of human basic fibroblast growth factor (FGF-2) in Bifidobacterium breve using a series of novel expression/secretion vectors Biotechnol Lett 30 1983 1988 10.1007/s10529-008-9772-8 1:CAS:528:DC%2BD1cXhtFCqsrnL 18575808
21. W Tang Y He S Zhou Y Ma G Liu 2009 A novel Bifidobacterium infantis-mediated TK/GCV suicide gene therapy system exhibits antitumor activity in a rat model of bladder cancer J Exp Clin Cancer Res 28 155 10.1186/1756-9966-28-155 20015348
22. MG Tovey C Maury 1999 Oral mucosal interferon therapy: marked antiviral and antitumor activity J Interferon Cytokine Res 19 145 155 10.1089/ 107999099314298 1:CAS:528:DyaK1MXhs1Wqt7s%3D 10090400
23. TE Tupasi VM Co MS Clarin ET Alesna EM Divinagracia NV Mangubat 2002 Randomized, double-blind, placebo-controlled trial of oromucosal low-dose interferon following prednisone withdrawal for chronic hepatitis B infection in Filipino patients Int J Infect Dis 6 37 41 10.1016/S1201-9712(02)90134-7 12044300
24. K Yazawa M Fujimori T Nakamura T Sasaki J Amano Y Kano S Taniguchi 2001 Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors Breast Cancer Res Treat 66 165 170 10.1023/A:1010644217648 1:CAS:528:DC%2BD3MXltFejurY%3D 11437103